Tech

BrainSee Enterprise software is reliable and accurate in detecting Alzheimer’s disease

ASNR Journal: BrainSee enterprise software is reliable and accurate in detecting Alzheimer’s disease

San Francisco, Calif. May 24, 2021: Today, the American Neuroradiology Society announced the Introducing Brain See. This is a summary of the 91% accuracy rate of a new AI-powered patented technology by Darmiyan Inc. that detects Alzheimer’s disease early. Of disease development. According to a publication published at ASNR’s annual meeting, the subtitle is “New MRI-based virtual microscopy technology for the non-invasive prognosis of amnestic MCI in clinical and clinical trials,” a major US and Canadian scholarship. Experts have confirmed the reliability of high testing and retesting. Overview of techniques available for research on early detection of Alzheimer’s-related mild cognitive impairment by non-invasive methods. Researchers pointed out that BrainSee is to facilitate the development of treatments for mild cognitive impairment and AD that can bridge the clinical gap.

To view the full announcement, including downloadable images, biography, etc. click here..

Important point:

  • Dalmiyan’s first product, BrainSee, is an AI-powered prognostic tool for understanding the progression of aMCI to Alzheimer’s disease, which has never been seen before. It works like a virtual microscope.
  • Darmiyan’s patented BrainSee software non-invasively illuminates neurodegeneration by analyzing human brain MRI, basic cognitive screening scores, and demographic information, and then providing an objective prognosis. ..
  • Damiyan’s team, a world-class leader in medicine, high-resolution microscopy, and neuroscience, has accumulated machine learning from more than 200 physicians, following cases of 5,000 MCI patients dating back decades. ..

Click on the image above to see the entire announcement.

San Francisco-based Dalmiyan, CA was founded in September 2016 and was backed by Y-Combinator (YC) in the summer of 2017. The company has won numerous awards and awards, including the 2018 TEDMED Hive Innovator, the 2019 CABHI Innovation Award, and the Fortune 40 Under. 40 for Healthcare in 2020. Darmiyan’s latest funding for 2020 was led by global pharmaceutical giant Eisai with the participation of YC and IT-Farm. Dalmiyan’s unique technology is patented in the United States. Patents are pending in Europe, Japan and China.

contact information:

Iris Beron

ILYSE@DARMIYAN.COM

Source: Dalmiyan

Distributor: Reportable, Inc.

BrainSee Enterprise software is reliable and accurate in detecting Alzheimer’s disease

Source link BrainSee Enterprise software is reliable and accurate in detecting Alzheimer’s disease

Related Articles

Back to top button